



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



SPM E-series LC-MS Mixture

Item No. 19417

Synonym: Specialized Pro-Resolving Mediator E-series LC-MS Mixture
Supplied as: A solution in ethanol (100 ng/ml of each compound)
Storage: -80°C
Stability: ≥5 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description


This mixture contains an E-series resolvins (specialized pro-resolving mediator; SPM) and its precursors, eicosapentaenoic acid (EPA; Item No. 90110) and (±)18-HEPE (Item No. 32840). The mixture is supplied in an amber ampule in which the headspace has been purged with argon to prevent lipid oxidation. This product has been designed for direct use in LC-MS applications. The solution may be serially diluted for preparation of calibrators and QC standards and/or used directly as a system suitability standard or tuning standard. After opening, we recommend that the mixture be transferred immediately to a 1 ml glass screw cap vial, to prevent solvent evaporation, and stored at -20°C. The mixture should be discarded after multiple freeze/thaw cycles.

The fatty acids in this mixture represent the metabolic cascade of the E-series resolvins. Resolvin E1 (Item No. 10007848) has been postulated to be an anti-inflammatory metabolite of EPA by way of an 18-HEPE intermediate.¹ It has been identified in mouse inflammatory exudates and in human plasma when subjects are treated with both aspirin (Item No. 70260) and supplemental EPA.²⁻⁴ Resolvin E1 has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.⁵⁻¹¹

Contents

SPM E series LCMS Mix QC
21APR2016_SPM_D_series_LCMS_Mix_QC_032 Sm (Mn, 3x3)

MRM of 3 Channels ES-
TIC
1.70e6



WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/28/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



References

1. Flower, R.J. and Perretti, M. Controlling inflammation: A fat chance? *J. Exp. Biol.* **201(5)**, 671-674 (2005).
2. Serhan, C.N., Clish, C.B., Brannon, J., *et al.* Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. *J. Exp. Med.* **192(8)**, 1197-1204 (2000).
3. Serhan, C.N., Hong, S., Gronert, K., *et al.* Resolvins: A family of bioactive products of ω -3 fatty acid transformation circuits by aspirin treatment that counter proinflammation signals. *J. Exp. Med.* **196(8)**, 1025-1037 (2002).
4. Arita, M., Bianchini, F., Aliberti, J., *et al.* Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. *J. Exp. Med.* **201(5)**, 713-722 (2005).
5. Arita, M., Yoshida, M., Hong, S., *et al.* Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. *Proc. Natl. Acad. Sci. USA* **102(21)**, 7671-7676 (2005).
6. Aoki, H., Hisada, T., Ishizuka, T., *et al.* Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. *Biochem. Biophys. Res. Commun.* **367**, 509-515 (2008).
7. Haworth, O., Cernadas, M., and Levy, B.D. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. *J. Immunol.* **186(11)**, 6129-6135 (2011).
8. Campbell, E.K., MacManus, C.F., Kominsky, D.J., *et al.* Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. *Proc. Natl. Acad. Sci. USA* **107(32)**, 14298-14303 (2010).
9. Hasturk, H., Abdallah, R., Kantarck, A., *et al.* Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* **35(5)**, 1123-1133 (2015).
10. Herrera, N.S., Hasturk, H., Kantarck, A., *et al.* Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. *Infect. Immun.* **83(2)**, 792-801 (2015).
11. Rajasagi, N.K., Reddy, P.B.J., Suryawanshi, A., *et al.* Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. *J. Immunol.* **186(3)**, 1735-1746 (2011).

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM